Journal of Antimicrobial Chemotherapy (2000) 46, 551-556
© 2000 The British Society for Antimicrobial Chemotherapy
In vitro activity of new generation fluoroquinolones against genotypically distinct and indistinguishable Clostridium difficile isolates
Department of Microbiology, University of Leeds and The General Infirmary, Leeds LS2 9JT, UK
We compared the activities of ciprofloxacin and levofloxacin with those of the newer fluoroquinolones grepafloxacin, moxifloxacin, sparfloxacin and trovafloxacin against Clostridium difficile isolates. As there is good evidence of marked clonal spread of C. difficile, we studied both genotypically distinct (n = 26) and indistinguishable (n = 28) isolates as determined by random amplified polymorphic DNA and ribosomal spacer PCR fingerprinting. The indistinguishable strains examined represent the main UK epidemic C. difficile clone. For 17 of 54 strains (31%) we were unable to read MICs following inocula preparation using Mueller–Hinton broth. Using Schaedler's broth for inocula preparation 93% of strains had readable MICs, although geometric mean MICs were uniformly higher (2.5- to 5.4-fold) compared with results using Mueller–Hinton broth. Moxifloxacin and trovafloxacin, followed by grepafloxacin, were the most active fluoroquinolones tested and were 3- to 4-fold more active than older agents such as ciprofloxacin by both MIC methods. Unexpectedly, clonal C. difficile strains had markedly reduced susceptibility compared with the distinct strains to each of the fluoroquinolones tested. Clonal strains were more than seven-fold or 12- to 29-fold less susceptible (according to geometric mean MICs) than distinct strains to both moxifloxacin and trovafloxacin, depending on the MIC method used. It remains to be seen whether the enhanced activity of new fluoroquinolones such as moxifloxacin in comparison with other fluoroquinolones against C. difficile implies that these agents are unlikely to be associated with C. difficile infection. However, clinical use of new generation fluoroquinolones in elderly hospitalized patients where C. difficile is endemic requires further study, particularly given the reduced antibiotic susceptibility to all fluoroquinolones of the readily transmissible UK C. difficile clone.
* Correspondence address. Department of Microbiology, University of Leeds, Leeds LS2 9JT, UK. Tel: +44-113-233-5595; Fax: +44-113-233-5649; E-mail: markwi{at}pathology.leeds.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  K. Saxton, S. D. Baines, J. Freeman, R. O'Connor, and M. H. Wilcox Effects of Exposure of Clostridium difficile PCR Ribotypes 027 and 001 to Fluoroquinolones in a Human Gut Model Antimicrob. Agents Chemother., February 1, 2009; 53(2): 412 - 420. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. D. Baines, R. O'Connor, J. Freeman, W. N. Fawley, C. Harmanus, P. Mastrantonio, E. J. Kuijper, and M. H. Wilcox Emergence of reduced susceptibility to metronidazole in Clostridium difficile J. Antimicrob. Chemother., November 1, 2008; 62(5): 1046 - 1052. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mutlu, A. J. Wroe, K. Sanchez-Hurtado, J. S. Brazier, and I. R. Poxton Molecular characterization and antimicrobial susceptibility patterns of Clostridium difficile strains isolated from hospitals in south-east Scotland J. Med. Microbiol., July 1, 2007; 56(7): 921 - 929. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Drudy, T. Quinn, R. O'Mahony, L. Kyne, P. O'Gaora, and S. Fanning High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile J. Antimicrob. Chemother., December 1, 2006; 58(6): 1264 - 1267. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. N. Fawley, P. Parnell, P. Verity, J. Freeman, and M. H. Wilcox Molecular Epidemiology of Endemic Clostridium difficile Infection and the Significance of Subtypes of the United Kingdom Epidemic Strain (PCR Ribotype 1) J. Clin. Microbiol., June 1, 2005; 43(6): 2685 - 2696. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K.A. O'Connor, M. Kingston, M. O'Donovan, B. Cryan, C. Twomey, and D. O'Mahony Antibiotic prescribing policy and Clostridium difficile diarrhoea QJM, July 1, 2004; 97(7): 423 - 429. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Ackermann, A. Degner, S. H. Cohen, J. Silva Jr, and A. C. Rodloff Prevalence and association of macrolide-lincosamide- streptogramin B (MLSB) resistance with resistance to moxifloxacin in Clostridium difficile J. Antimicrob. Chemother., March 1, 2003; 51(3): 599 - 603. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Ortiz-de-Saracho, L. Pantoja, M. J. Romero, and R. Lopez Moxifloxacin-induced Clostridium difficile diarrhea Ann. Pharmacother., March 1, 2003; 37(3): 452 - 453. [Full Text] [PDF]
|
|
|
|
|
|
L. Dridi, J. Tankovic, B. Burghoffer, F. Barbut, and J.-C. Petit gyrA and gyrB Mutations Are Implicated in Cross-Resistance to Ciprofloxacin and Moxifloxacin in Clostridium difficile Antimicrob. Agents Chemother., November 1, 2002; 46(11): 3418 - 3421. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Mylonakis, E. T. Ryan, and S. B. Calderwood Clostridium difficile-Associated Diarrhea: A Review Arch Intern Med, February 26, 2001; 161(4): 525 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Freeman and M. H. Wilcox Antibiotic activity against genotypically distinct and indistinguishable Clostridium difficile isolates J. Antimicrob. Chemother., February 1, 2001; 47(2): 244 - 246. [Full Text] [PDF]
|
|